Acute Myeloid Leukemia

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA guidance · 2013-11-22
European Medicines Agency recommends changes in use of leukaemia medicine Iclusig (ponatinib) in order to minimise risk of blood clots
EMA recommends changes in how ponatinib (Iclusig) is used to reduce the risk of blood clots in leukemia treatment.